Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC
More than 90% of patients with locally advanced basal cell carcinoma (BCC) of the head and neck achieved locoregional control (LRC) with vismodegib (Erivedge) and radiation therapy (RT), a small clinical trial showed. LRC at 1 year was 91% after vismodegib induction therapy followed by concurrent vismodegib and RT. The overall response rate was 63% […]